NEWSROOM

Press Releases

In the News

Logo & Resources Library

Recent News

A time like no other for lupus clinical research

On “Endpoints Clinical Trials Day,” Lupus Therapeutics EVP Expresses Optimism About the Current State of Lupus Research

New York, NY, December 17, 2024 — Today is “Endpoints Clinical Trials Day,” hosted by international biopharma news outlet Endpoints News....

Request for Applications: see article for details

Lupus Therapeutics Announces a New, Groundbreaking Mechanism to Fund Clinical Studies Addressing the Impact of Diet, Nutrition, and Microbiome on Lupus

New York, NY, November 22, 2024 — The unique IDEAL (Investigate Dietary Approaches for Lupus) Initiative will provide multidisciplinary research teams the...

LRA Spotlight on ACR Convergence 2024: Lupus Therapeutics-Supported Clinical Research and More

New York, NY, November 21, 2024 — New ACR guidelines for advancing the management of lupus nephritis (LN). Novel approaches...

News from ACR Convergence 2024

Lupus Therapeutics Statement on Phase 3 PHOENYCS GO Positive Data In Moderate-To-Severe Systemic Lupus

Washington, DC, November 19, 2024 – Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance (LRA), is encouraged...

News from ACR Convergence 2024

ACR Released a Summary of the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis

Washington, DC, November 18, 2024 — The American College of Rheumatology (ACR) released a summary of the 2024 ACR Guideline...

Announcing LRA-supported research studies at ACR

Lupus Research Alliance Announces Lupus Research Highlights at ACR Convergence 2024

New York, NY, November 4, 2024 – Sixteen presentations of preclinical studies funded by the Lupus Research Alliance to advance understanding...

Gazyva® Shows Positive Results in Phase 3 Lupus Nephritis Trial

New York, NY, September 25, 2024 — The Lupus Research Alliance (LRA) and clinical research affiliate Lupus Therapeutics (LT) are...

Investigational Treatment Dapirolizumab Pegol Shows Positive Results in Phase 3 Clinical Trial

New York, NY, September 24, 2024 — Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is proud...

Statement in Response to Recent Lupus Science and Medicine Publication

New York, NY, July 16, 2024 — A study recently published in Lupus Science and Medicine showed that krill oil...

On “Lupus Call to Action Day”, the Lupus Research Alliance and Lupus Therapeutics Amplify a Call for Equity and Inclusion

New York, NY, May 1, 2024 — As part of Lupus Awareness Month, May 1 has been declared “Lupus Call...

Lupus Peer-to-Peer Early Education Program Expands

New York, NY, March 28, 2024 — Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, has announced...

Lupus Therapeutics Announces Collaboration to Support the Evaluation of Non-Genetically Modified Cell-Based Therapy for Lupus Nephritis with Artiva Biotherapeutics

New York, NY, March 14, 2024 — Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announced a...